Hepatitis C News

A treatment regimen of low dose VBI-2601 (BRII-179) injections in patients with chronic hepatitis B exhibited positive safety, tolerability and efficacy, according to a poster presented at the International Liver Congress.

Routine testing for bloodborne viruses in EDs proved easily integrated and cost-effective in the U.K., according to a presentation at The International Liver Congress.

Researchers validated a liver cancer risk test algorithm for identifying patients with chronic hepatitis C at low risk for hepatocellular carcinoma, according to a study presented at The Digital International Liver Congress.

Administration of direct-acting antiviral agents safely and effectively treated children with hepatitis C, according to a presentation at the International Liver Congress.

Intelligent liver function testing successfully identified patients with hepatitis C who were previously undiagnosed, many of whom did not fit traditional at-risk profiles, according to a presentation at the International Liver Conference.

VIR-2218, an investigational small interfering ribonucleic acid therapeutic, was well tolerated in patients for the treatment of chronic hepatitis B virus, according to research presented at the International Liver Congress.

Researchers called for immediate treatment action without restriction among patients with hepatitis C for continued progress in virus elimination following COVID-19, according to a presentation at The Digital International Liver Congress.

Ultrasound quality changed between examinations for hepatocellular carcinoma detection in patients with cirrhosis, according to research published in Clinical Gastroenterology and Hepatology.

Ravidasvir in addition to sofosbuvir was safe and effective in the treatment of patients with chronic hepatitis C virus, according to research published in The Lancet Gastroenterology and Hepatology.

Groundbreaking developments in HIV treatment are transitioning the disease into a chronic condition. Thankfully, patients can live long and full lives, but other challenges arise, particularly for those living with both HIV and the hepatitis C virus.